<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37545536</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>08</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>08</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Low T-cell reactivity to TDP-43 peptides in ALS.</ArticleTitle><Pagination><StartPage>1193507</StartPage><MedlinePgn>1193507</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1193507</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2023.1193507</ELocationID><Abstract><AbstractText Label="BACKGROUND">Dysregulation of the immune system in amyotrophic lateral sclerosis (ALS) includes changes in T-cells composition and infiltration of T cells in the brain and spinal cord. Recent studies have shown that cytotoxic T cells can directly induce motor neuron death in a mouse model of ALS and that T cells from ALS patients are cytotoxic to iPSC-derived motor neurons from ALS patients. Furthermore, a clonal expansion to unknown epitope(s) was recently found in familial ALS and increased peripheral and intrathecal activation of cytotoxic CD8<sup>+</sup> T cells in sporadic ALS.</AbstractText><AbstractText Label="RESULTS">Here, we show an increased activation of peripheral T cells from patients with sporadic ALS by IL-2 treatment, suggesting an increase of antigen-experienced T cells in ALS blood. However, a putative antigen for T-cell activation in ALS has not yet been identified. Therefore, we investigated if peptides derived from TDP-43, a key protein in ALS pathogenesis, can act as epitopes for antigen-mediated activation of human T cells by ELISPOT and flow cytometry. We found that TDP-43 peptides induced only a weak MHCI or MHCII-restricted activation of both na&#xef;ve and antigen-experienced T cells from healthy controls and ALS patients. Interestingly, we found less activation in T cells from ALS patients to TDP-43 and control stimuli. Furthermore, we found no change in the levels of naturally occurring auto-antibodies against full-length TDP-43 in ALS.</AbstractText><AbstractText Label="CONCLUSION">Our data suggests a general increase in antigen-experienced T cells in ALS blood, measured by <i>in-vitro</i> culture with IL-2 for 14 days. Furthermore, it suggests that TDP-43 is a weak autoantigen.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Ramachandran, Grozdanov, Leins, Kandler, Witzel, Mulaw, Ludolph, Weishaupt and Danzer.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ramachandran</LastName><ForeName>Swetha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neurology, University Clinic, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grozdanov</LastName><ForeName>Veselin</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Neurology, University Clinic, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leins</LastName><ForeName>Bianca</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Neurology, University Clinic, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kandler</LastName><ForeName>Katharina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Neurology, University Clinic, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Witzel</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neurology, University Clinic, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mulaw</LastName><ForeName>Medhanie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Experimental Cancer Research, Medical Faculty, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ludolph</LastName><ForeName>Albert C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Neurology, University Clinic, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weishaupt</LastName><ForeName>Jochen H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Neurology, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Danzer</LastName><ForeName>Karin M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Neurology, University Clinic, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Ulm, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007376">Interleukin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C531617">Amyotrophic lateral sclerosis 1</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007376" MajorTopicYN="N">Interleukin-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">T cells</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">autoantibody</Keyword><Keyword MajorTopicYN="N">autoantigen</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>7</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>7</Day><Hour>4</Hour><Minute>25</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37545536</ArticleId><ArticleId IdType="pmc">PMC10401033</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2023.1193507</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhao W, Beers DR, Appel SH. Immune-mediated mechanisms in the pathoprogression of amyotrophic lateral sclerosis. J Neuroimmune Pharmacol (2013) 8:888&#x2013;99. doi: 10.1007/s11481-013-9489-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11481-013-9489-x</ArticleId><ArticleId IdType="pmc">PMC4126425</ArticleId><ArticleId IdType="pubmed">23881705</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawamata T, Akiyama H, Yamada T, Mcgeer PL. Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am J Pathol (1992) 140:691&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1886170</ArticleId><ArticleId IdType="pubmed">1347673</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelhardt JI, Tajti J, Appel SH. Lymphocytic infiltrates in the spinal cord in amyotrophic lateral sclerosis. Arch Neurol (1993) 50:30&#x2013;6. doi: 10.1001/archneur.1993.00540010026013</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.1993.00540010026013</ArticleId><ArticleId IdType="pubmed">8093428</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Brettschneider J, Ludolph AC, Lee VM, Trojanowski JQ, Del Tredici K. Amyotrophic lateral sclerosis&#x2013;a model of corticofugal axonal spread. Nat Rev Neurol (2013) 9:708&#x2013;14. doi: 10.1038/nrneurol.2013.221</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2013.221</ArticleId><ArticleId IdType="pmc">PMC3943211</ArticleId><ArticleId IdType="pubmed">24217521</ArticleId></ArticleIdList></Reference><Reference><Citation>Zondler L, Muller K, Khalaji S, Bliederhauser C, Ruf WP, Grozdanov V, et al. . Peripheral monocytes are functionally altered and invade the CNS in ALS patients. Acta Neuropathol (2016) 132:391&#x2013;411. doi: 10.1007/s00401-016-1548-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1548-y</ArticleId><ArticleId IdType="pubmed">26910103</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Zhao W, Wang J, Zhang X, Wen S, Neal D, et al. . ALS patients' regulatory T lymphocytes are dysfunctional, and correlate with disease progression rate and severity. JCI Insight (2017) 2:e89530. doi: 10.1172/jci.insight.89530</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.89530</ArticleId><ArticleId IdType="pmc">PMC5333967</ArticleId><ArticleId IdType="pubmed">28289705</ArticleId></ArticleIdList></Reference><Reference><Citation>Thonhoff JR, Beers DR, Zhao W, Pleitez M, Simpson EP, Berry JD, et al. . Expanded autologous regulatory T-lymphocyte infusions in ALS: a phase I, first-in-human study. Neurol Neuroimmunol Neuroinflamm (2018) 5:e465. doi: 10.1212/NXI.0000000000000465</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000465</ArticleId><ArticleId IdType="pmc">PMC5961523</ArticleId><ArticleId IdType="pubmed">29845093</ArticleId></ArticleIdList></Reference><Reference><Citation>Giovannelli I, Heath P, Shaw PJ, Kirby J. The involvement of regulatory T cells in amyotrophic lateral sclerosis and their therapeutic potential. Amyotroph Lateral Scler Frontotemporal Degener (2020) 21(5-6):435&#x2013;444. doi: 10.1080/21678421.2020.1752246</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1752246</ArticleId><ArticleId IdType="pubmed">32484719</ArticleId></ArticleIdList></Reference><Reference><Citation>Coque E, Salsac C, Espinosa-Carrasco G, Varga B, Degauque N, Cadoux M, et al. . Cytotoxic CD8(+) T lymphocytes expressing ALS-causing SOD1 mutant selectively trigger death of spinal motoneurons. Proc Natl Acad Sci U.S.A. (2019) 116:2312&#x2013;7. doi:&#xa0;10.1073/pnas.1815961116</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1815961116</ArticleId><ArticleId IdType="pmc">PMC6369778</ArticleId><ArticleId IdType="pubmed">30674678</ArticleId></ArticleIdList></Reference><Reference><Citation>Campisi L, Chizari S, Ho JSY, Gromova A, Arnold FJ, Mosca L, et al. . Clonally expanded CD8 T cells characterize amyotrophic lateral sclerosis-4. Nature (2022) 606:945&#x2013;52. doi: 10.1038/s41586-022-04844-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04844-5</ArticleId><ArticleId IdType="pmc">PMC10089623</ArticleId><ArticleId IdType="pubmed">35732742</ArticleId></ArticleIdList></Reference><Reference><Citation>Rolfes L, Schulte-Mecklenbeck A, Schreiber S, Vielhaber S, Herty M, Marten A, et al. . Amyotrophic lateral sclerosis patients show increased peripheral and intrathecal T-cell activation. Brain Commun (2021) 3:fcab157. doi: 10.1093/braincomms/fcab157</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcab157</ArticleId><ArticleId IdType="pmc">PMC8363480</ArticleId><ArticleId IdType="pubmed">34405141</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigues Lima-Junior J, Sulzer D, Lindestam Arlehamn CS, Sette A. The role of immune-mediated alterations and disorders in ALS disease. Hum Immunol (2021) 82:155&#x2013;61. doi: 10.1016/j.humimm.2021.01.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.humimm.2021.01.017</ArticleId><ArticleId IdType="pmc">PMC7942756</ArticleId><ArticleId IdType="pubmed">33583639</ArticleId></ArticleIdList></Reference><Reference><Citation>Sulzer D, Alcalay RN, Garretti F, Cote L, Kanter E, Agin-Liebes J, et al. . T Cells from patients with parkinson's disease recognize alpha-synuclein peptides. Nature (2017) 546:656&#x2013;61. doi: 10.1038/nature22815</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature22815</ArticleId><ArticleId IdType="pmc">PMC5626019</ArticleId><ArticleId IdType="pubmed">28636593</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al. . Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science (2006) 314:130&#x2013;3. doi: 10.1126/science.1134108</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, et al. . TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science (2008) 319:1668&#x2013;72. doi: 10.1126/science.1154584</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1154584</ArticleId><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M. Molecular neuropathology of TDP-43 proteinopathies. Int J Mol Sci (2009) 10:232&#x2013;46. doi: 10.3390/ijms10010232</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms10010232</ArticleId><ArticleId IdType="pmc">PMC2662455</ArticleId><ArticleId IdType="pubmed">19333444</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Kwong LK, Lee EB, Kremmer E, Flatley A, Xu Y, et al. . Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathologica (2009) 117:137&#x2013;49. doi: 10.1007/s00401-008-0477-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-008-0477-9</ArticleId><ArticleId IdType="pmc">PMC2693625</ArticleId><ArticleId IdType="pubmed">19125255</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph AC, Brettschneider J. TDP-43 in amyotrophic lateral sclerosis - is it a prion disease? Eur J Neurol (2015) 22:753&#x2013;61. doi: 10.1111/ene.12706</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12706</ArticleId><ArticleId IdType="pubmed">25846565</ArticleId></ArticleIdList></Reference><Reference><Citation>Suk TR, Rousseaux MWC. The role of TDP-43 mislocalization in amyotrophic lateral sclerosis. Mol Neurodegener (2020) 15:45. doi: 10.1186/s13024-020-00397-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-020-00397-1</ArticleId><ArticleId IdType="pmc">PMC7429473</ArticleId><ArticleId IdType="pubmed">32799899</ArticleId></ArticleIdList></Reference><Reference><Citation>Vita R, Overton JA, Greenbaum JA, Ponomarenko J, Clark JD, Cantrell JR, et al. . The immune epitope database (IEDB) 3.0. Nucleic Acids Res (2015) 43:D405&#x2013;412. doi: 10.1093/nar/gku938</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gku938</ArticleId><ArticleId IdType="pmc">PMC4384014</ArticleId><ArticleId IdType="pubmed">25300482</ArticleId></ArticleIdList></Reference><Reference><Citation>Vita R, Mahajan S, Overton JA, Dhanda SK, Martini S, Cantrell JR, et al. . The immune epitope database (IEDB): 2018 update. Nucleic Acids Res (2019) 47:D339&#x2013;43. doi: 10.1093/nar/gky1006</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gky1006</ArticleId><ArticleId IdType="pmc">PMC6324067</ArticleId><ArticleId IdType="pubmed">30357391</ArticleId></ArticleIdList></Reference><Reference><Citation>Rammensee HG, Bachmann J, Emmerich NPN, Bachor OA, Stevanovid S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics (1999) 50(3):213&#x2013;9. doi: 10.1007/s002510050595</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s002510050595</ArticleId><ArticleId IdType="pubmed">10602881</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasteiger E, Hoogland C, Gattiker A, S.e. Duvaud MR, Wilkins K.L, Appel RD, Bairoch A. Protein identification and analysis tools on the ExPASy server. In: Walker JM, editor. The proteomics protocols handbook. Totowa, NJ: Humana Press; (2005). p. 571&#x2013;607.</Citation></Reference><Reference><Citation>Wilhelm M, Schlegl J, Hahne H, Gholami AM, Lieberenz M, Savitski MM, et al. . Mass-spectrometry-based draft of the human proteome. Nature (2014) 509(7502):582&#x2013;7. doi: 10.1038/nature13319</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature13319</ArticleId><ArticleId IdType="pubmed">24870543</ArticleId></ArticleIdList></Reference><Reference><Citation>Rawlings ND, Barrett AJ, Thomas PD, Huang X, Bateman A, Finn RD. The MEROPS database of proteolytic enzymes, their substrates and inhibitors in 2017 and a comparison with peptidases in the PANTHER database. Nucleic Acids Res (2018) 46(D1):D624&#x2013;32. doi: 10.1093/nar/gkx1134</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkx1134</ArticleId><ArticleId IdType="pmc">PMC5753285</ArticleId><ArticleId IdType="pubmed">29145643</ArticleId></ArticleIdList></Reference><Reference><Citation>Grozdanov V, Bliederhaeuser C, Ruf WP, Roth V, Fundel-Clemens K, Zondler L, et al. . Inflammatory dysregulation of blood monocytes in parkinson's disease patients. Acta Neuropathol (2014) 128:651&#x2013;63. doi: 10.1007/s00401-014-1345-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1345-4</ArticleId><ArticleId IdType="pmc">PMC4201759</ArticleId><ArticleId IdType="pubmed">25284487</ArticleId></ArticleIdList></Reference><Reference><Citation>Feiler MS, Strobel B, Freischmidt A, Helferich AM, Kappel J, Brewer BM, et al. . TDP-43 is intercellularly transmitted across axon terminals. J Cell Biol (2015) 211:897&#x2013;911. doi: 10.1083/jcb.201504057</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201504057</ArticleId><ArticleId IdType="pmc">PMC4657165</ArticleId><ArticleId IdType="pubmed">26598621</ArticleId></ArticleIdList></Reference><Reference><Citation>Bliederhaeuser C, Grozdanov V, Speidel A, Zondler L, Ruf WP, Bayer H, et al. . Age-dependent defects of alpha-synuclein oligomer uptake in microglia and monocytes. Acta Neuropathol (2016) 131:379&#x2013;91. doi: 10.1007/s00401-015-1504-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1504-2</ArticleId><ArticleId IdType="pubmed">26576561</ArticleId></ArticleIdList></Reference><Reference><Citation>
R Core Team . (2022) R: A language and environment for statistical computing. (Vienna, Austria: R Foundation for Statistical Computing; ). Available at: https://www.R-project.org/.</Citation></Reference><Reference><Citation>Nyland H, Naess A. T Lymphocytes in peripheral blood from patients with neurological diseases. Acta Neurol Scand (1978) 58:272&#x2013;9. doi: 10.1111/j.1600-0404.1978.tb02887.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0404.1978.tb02887.x</ArticleId><ArticleId IdType="pubmed">310624</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Feng W, Huang R, Guo X, Chen Y, Zheng Z, et al. . Evidence for peripheral immune activation in amyotrophic lateral sclerosis. J Neurol Sci (2014) 347:90&#x2013;5. doi: 10.1016/j.jns.2014.09.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2014.09.025</ArticleId><ArticleId IdType="pubmed">25312013</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock BJ, Zhou T, Kashlan SR, Little RJ, Goutman SA, Feldman EL. Correlation of peripheral immunity with rapid amyotrophic lateral sclerosis progression. JAMA Neurol (2017) 74:1446&#x2013;54. doi: 10.1001/jamaneurol.2017.2255</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.2255</ArticleId><ArticleId IdType="pmc">PMC5822195</ArticleId><ArticleId IdType="pubmed">28973548</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, McGeer EG. Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve (2002) 26(4):459&#x2013;70. doi: 10.1002/mus.10191</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.10191</ArticleId><ArticleId IdType="pubmed">12362410</ArticleId></ArticleIdList></Reference><Reference><Citation>Zorn E, Nelson EA, Mohseni M, Porcheray F, Kim H, Litsa D, et al. . IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo . Blood (2006) 108:1571&#x2013;9. doi: 10.1182/blood-2006-02-004747</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2006-02-004747</ArticleId><ArticleId IdType="pmc">PMC1895505</ArticleId><ArticleId IdType="pubmed">16645171</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Q, Adams JY, Penaranda C, Melli K, Piaggio E, Sgouroudis E, et al. . Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity (2008) 28:687&#x2013;97. doi: 10.1016/j.immuni.2008.03.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2008.03.016</ArticleId><ArticleId IdType="pmc">PMC2394854</ArticleId><ArticleId IdType="pubmed">18468463</ArticleId></ArticleIdList></Reference><Reference><Citation>Nardo G, Trolese MC, Bendotti C. Major histocompatibility complex I expression by motor neurons and its implication in amyotrophic lateral sclerosis. Front Neurol (2016) 7:89. doi: 10.3389/fneur.2016.00089</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2016.00089</ArticleId><ArticleId IdType="pmc">PMC4904147</ArticleId><ArticleId IdType="pubmed">27379008</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveira AL, Thams S, Lidman O, Piehl F, Hokfelt T, Karre K, et al. . A role for MHC class I molecules in synaptic plasticity and regeneration of neurons after axotomy. Proc Natl Acad Sci U.S.A. (2004) 101:17843&#x2013;8. doi:&#xa0;10.1073/pnas.0408154101</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0408154101</ArticleId><ArticleId IdType="pmc">PMC539738</ArticleId><ArticleId IdType="pubmed">15591351</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F. Molecular mechanisms of IFN-gamma to up-regulate MHC class I antigen processing and presentation. Int Rev Immunol (2009) 28:239&#x2013;60. doi: 10.1080/08830180902978120</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08830180902978120</ArticleId><ArticleId IdType="pubmed">19811323</ArticleId></ArticleIdList></Reference><Reference><Citation>Volc D, Poewe W, Kutzelnigg A, Luhrs P, Thun-Hohenstein C, Schneeberger A, et al. . Safety and immunogenicity of the alpha-synuclein active immunotherapeutic PD01A in patients with parkinson's disease: a randomised, single-blinded, phase 1 trial. Lancet Neurol (2020) 19:591&#x2013;600. doi: 10.1016/S1474-4422(20)30136-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30136-8</ArticleId><ArticleId IdType="pubmed">32562684</ArticleId></ArticleIdList></Reference><Reference><Citation>Conti E, Sala G, Diamanti S, Casati M, Lunetta C, Gerardi F, et al. . Serum naturally occurring anti-TDP-43 auto-antibodies are increased in amyotrophic lateral sclerosis. Sci Rep (2021) 11:1978. doi: 10.1038/s41598-021-81599-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-81599-5</ArticleId><ArticleId IdType="pmc">PMC7820419</ArticleId><ArticleId IdType="pubmed">33479441</ArticleId></ArticleIdList></Reference><Reference><Citation>Simula ER, Arru G, Zarbo IR, Solla P, Sechi LA. TDP-43 and HERV-K envelope-specific immunogenic epitopes are recognized in ALS patients. Viruses (2021) 13. doi: 10.3390/v13112301</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13112301</ArticleId><ArticleId IdType="pmc">PMC8623164</ArticleId><ArticleId IdType="pubmed">34835107</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen AK, Folke J, Owczarek S, Svenstrup K, Winge K, Pakkenberg B, et al. . TDP-43-specific autoantibody decline in patients with amyotrophic lateral sclerosis. Neurol Neuroimmunol Neuroinflamm (2021) 8. doi: 10.1212/NXI.0000000000000937</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000937</ArticleId><ArticleId IdType="pmc">PMC7768943</ArticleId><ArticleId IdType="pubmed">33361387</ArticleId></ArticleIdList></Reference><Reference><Citation>Alam MM, Yang D, Trivett AL, Li X-Q, Oppenheim JJ. Alpha-synuclein (&#x3b1;S) acts as an alarmin to promote dendritic cell activation and proinflammatory immune response. J Immunol (2019) 202:68.17&#x2013;7. doi: 10.4049/jimmunol.202.Supp.68.17</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.202.Supp.68.17</ArticleId></ArticleIdList></Reference><Reference><Citation>Grozdanov V, Bousset L, Hoffmeister M, Bliederhaeuser C, Meier C, Madiona K, et al. . Increased immune activation by pathologic alpha-synuclein in parkinson's disease. Ann Neurol (2019) 86:593&#x2013;606. doi: 10.1002/ana.25557</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25557</ArticleId><ArticleId IdType="pubmed">31343083</ArticleId></ArticleIdList></Reference><Reference><Citation>Schetters STT, Gomez-Nicola D, Garcia-Vallejo JJ, Van Kooyk Y. Neuroinflammation: microglia and T cells get ready to tango. Front Immunol (2017) 8:1905. doi:&#xa0;10.3389/fimmu.2017.01905</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01905</ArticleId><ArticleId IdType="pmc">PMC5788906</ArticleId><ArticleId IdType="pubmed">29422891</ArticleId></ArticleIdList></Reference><Reference><Citation>Mcgeer PL, Itagaki S, Mcgeer EG. Expression of the histocompatibility glycoprotein HLA-DR in neurological disease. Acta Neuropathol (1988) 76:550&#x2013;7. doi: 10.1007/BF00689592</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00689592</ArticleId><ArticleId IdType="pubmed">2974227</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel JS, Engelhardt JI, Siklos L, Simpson EP, Kim SH, Pan T, et al. . Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann Neurol (2004) 55:221&#x2013;35. doi: 10.1002/ana.10805</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.10805</ArticleId><ArticleId IdType="pubmed">14755726</ArticleId></ArticleIdList></Reference><Reference><Citation>Troost D, Van Den Oord JJ, De Jong JM, Swaab DF. Lymphocytic infiltration in the spinal cord of patients with amyotrophic lateral sclerosis. Clin Neuropathol (1989) 8:289&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">2533530</ArticleId></ArticleIdList></Reference><Reference><Citation>Troost D, Van Den Oord JJ, Vianney De Jong JM. Immunohistochemical characterization of the inflammatory infiltrate in amyotrophic lateral sclerosis. Neuropathol Appl Neurobiol (1990) 16:401&#x2013;10. doi: 10.1111/j.1365-2990.1990.tb01276.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2990.1990.tb01276.x</ArticleId><ArticleId IdType="pubmed">2263315</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>